1,1,3,3-Tetramethyl-1,3-disila-2-oxa[3]ferrocenophane: improved synthesis and new crystal structure

Ch Hartinger , T.H Brehmer , G Giester , M Galanski
Inorganica Chimica Acta 328 ( 1) 237 -240

4
2002
Maltol‐Derived Ruthenium–Cymene Complexes with Tumor Inhibiting Properties: The Impact of Ligand–Metal Bond Stability on Anticancer Activity In Vitro

Wolfgang Kandioller , Christian G. Hartinger , Alexey A. Nazarov , Caroline Bartel
Chemistry: A European Journal 15 ( 45) 12283 -12291

97
2009
An Internal Fluorescent Probe Based on Anthracene to Evaluate Cation-Anion Interactions in Imidazolium Salts

Zhaofu Fei , Dun‐Ru Zhu , Xue Yang , Lingjie Meng
Chemistry: A European Journal 16 ( 22) 6473 -6481

24
2010
Phosphite-derivatized ruthenium-carbohydrate complexes in the catalytic hydration of nitriles. short communication.

Shaheen M. Ashraf , Isabella Berger , Alexey A. Nazarov , Christian G. Hartinger
Chemistry & Biodiversity 5 ( 8) 1640 -1644

20
2008
The Hydration of Chloroacetonitriles Catalyzed by Mono- and Dinuclear Ru II - and Os II -Arene Complexes

Shaheen M. Ashraf , Wolfgang Kandioller , Maria-Grazia Mendoza-Ferri , Alexey A. Nazarov
Chemistry & Biodiversity 5 ( 10) 2060 -2066

26
2008
A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin?

Isabella Berger , Alexey A. Nazarov , Christian G. Hartinger , Michael Groessl
ChemMedChem 2 ( 4) 505 -514

40
2007
Cover Picture: A glucose derivative as natural alternative to the cyclohexane‐1,2‐diamine ligand in the anticancer drug oxaliplatin? (ChemMedChem 4/2007)

Isabella Berger , Alexey A. Nazarov , Christian G. Hartinger , Michael Groessl
ChemMedChem 2 ( 4) 385 -385

2007
In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands.

Isabella Berger , Muhammad Hanif , Alexey A Nazarov , Christian G Hartinger
Chemistry: A European Journal 14 ( 29) 9046 -9057

88
2008
Glucose ferrocenyl-oxazolines : Coordination behavior toward [Pd(η3-allyl)Cl]2 studied by ESI-MS

Ch.G. Hartinger , A.A. Nazarov , M. Galanski , M. Reithofer
Journal of Organometallic Chemistry 690 ( 14) 3301 -3308

14
2005
A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins

F. Piccioli , S. Sabatini , L. Messori , P. Orioli
Journal of Inorganic Biochemistry 98 ( 6) 1135 -1142

69
2004
Dalton Discussion 10: Applications of Metals in Medicine and Healthcare

Reviewed by Christian G. Hartinger
Platinum Metals Review 52 ( 2) 96 -99

2
2008
Resistance against novel anticancer metal compounds: differences and similarities

P HEFFETER , U JUNGWIRTH , M JAKUPEC , C HARTINGER
Drug Resistance Updates 11 ( 1) 1 -16

175
2008
Organometallic Anticancer Agents: Bioactive Ligand Systems as Key Elements Determining the Biological Properties

C Hartinger , S Meier , A Kurzwernhart , M Babak
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY 19 S189 -S189

2014
Metabolism of organometallic Ru compounds with antimetastatic activity

A Bytzek , C Hartinger , P Dyson , BH Keppler

2009
2007
2007
The phase diagram and optical properties of La\V Sr V MnO for x) 0.2

M Paraskevopoulos , F Mayr , C Hartinger , A Pimenov

Advances in Solid State Physics

R Hackl , L Tassini , F Venturini , C Hartinger
Springer-Verlag 225 -225

10
2005
The phase diagram and optical properties of La {sub 1-x} Sr {sub x} MnO {sub 3} for x {<=} 0.2

M Paraskevopoulos , F Mayr , C Hartinger , A Pimenov
Journal of Magnetism and Magnetic Materials 211

2000